A Randomized Trial to Determine the Tolerability and Immunogenicity of a Quadrivalent Meningococcal Glycoconjugate Vaccine in Healthy Adolescents-Reference-Cited by-同舟云学术

A Randomized Trial to Determine the Tolerability and Immunogenicity of a Quadrivalent Meningococcal Glycoconjugate Vaccine in Healthy Adolescents

Published:2009-02 Issue:2 Volume:28 Page:86-91
ISSN:0891-3668
Container-title:Pediatric Infectious Disease Journal
language:en
Short-container-title:

Author:

Jackson Lisa A.,Jacobson Robert M.,Reisinger Keith S.,Anemona Alessandra,Danzig Lisa E.,Dull Peter M.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Microbiology (medical),Pediatrics, Perinatology, and Child Health

Reference18 articles.

1. Human immunity to the meningococcus. I. The role of humoral antibodies.;Goldschneider;J Exp Med,1969

2. Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine.;Reingold;Lancet,1985

3. Effectiveness of a mass immunization campaign against serogroup C meningococcal disease in Quebec.;De Wals;JAMA,2001

4. Evolution of conjugate vaccines.;Makela;Expert Rev Vaccines,2002

5. Revised recommendations of the Advisory Committee on Immunization Practices to vaccinate all persons aged 11–18 years with meningococcal conjugate vaccine.;MMWR,2007

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Aluminium adjuvants versus placebo or no intervention in vaccine randomised clinical trials: a systematic review with meta-analysis and Trial Sequential Analysis;BMJ Open;2022-06

2. Immunological non-inferiority of a new fully liquid presentation of the MenACWY-CRM vaccine to the licensed vaccine: results from a randomized, controlled, observer-blind study in adolescents and young adults;Human Vaccines & Immunotherapeutics;2021-10-06

3. Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020;MMWR. Recommendations and Reports;2020-09-25

4. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in ≥56-year-olds: A Phase III randomized study;Vaccine;2020-06

5. Results from a large post-marketing safety surveillance study in the Republic of Korea with a quadrivalent meningococcal CRM-conjugate vaccine in individuals aged 2 months–55 years;Human Vaccines & Immunotherapeutics;2019-10-25